Manufacturer of Controlled Substances; Notice of Application; Sigma Aldrich Research Biochemicals, Inc., 12102-12103 [2013-03893]
Download as PDF
<![CDATA[
12102
Federal Register / Vol. 78, No. 35 / Thursday, February 21, 2013 / Notices
for commercial distribution in the
United States.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
listed in schedule II, which falls under
the authority of section 1002(a)(2)(B) of
the Act 21 U.S.C. 952(a)(2)(B) may, in
the circumstances set forth in 21 U.S.C.
958(i), file comments or objections to
the issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than March 25, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03902 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
erowe on DSK2VPTVN1PROD with NOTICES
Manufacturer of Controlled
Substances; Notice of Application;
Mallinckrodt, LLC
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 30,
2012, Mallinckrodt, LLC, 3600 North
Second Street, St. Louis, Missouri
63147, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
VerDate Mar<15>2010
14:47 Feb 20, 2013
Jkt 229001
manufacturer of the following basic
classes of controlled substances:
Drug
Schedule
Tetrahydrocannabinols (7370) .....
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Norlevorphanol (9634) ..................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Nabilone (7379) ............................
4-Anilino-N-phenethyl-4-piperidine
(8333).
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The firm plans to manufacture the
listed controlled substances for internal
use and for sale to other companies.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03892 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Pharmagra Labs, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on December 3, 2012,
Pharmagra Labs, Inc., 158 McLean Road,
Brevard, North Carolina 28712, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
pentobarbital (2270), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed substance for analytical
research and clinical trials.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03888 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Sigma Aldrich Research Biochemicals,
Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 21,
2012, Sigma Aldrich Research
Biochemicals, Inc., 1–3 Strathmore
Road, Natick, Massachusetts 01760–
2447, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following classes of
controlled substances:
Drug
Cathinone (1235) ..........................
Methcathinone (1237) ..................
E:\FR\FM\21FEN1.SGM
21FEN1
Schedule
I
I
12103
Federal Register / Vol. 78, No. 35 / Thursday, February 21, 2013 / Notices
Drug
Schedule
erowe on DSK2VPTVN1PROD with NOTICES
Aminorex (1585) ...........................
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
Psilocybin (7437) ..........................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
1-[1-(2Thienyl)cyclohexyl]piperidine
(TCP) (7470).
N-Benzylpiperazine (BZP) (7493)
Heroin (9200) ...............................
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Nabilone (7379) ............................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Ecgonine (9180) ...........................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Meperidine (9230) ........................
Metazocine (9240) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Remifentanil (9739) ......................
Carfentanil (9743) .........................
Fentanyl (9801) ............................
I
I
I
I
I
14:47 Feb 20, 2013
BILLING CODE 4410–09–P
I
DEPARTMENT OF JUSTICE
I
Drug Enforcement Administration
I
Manufacturer of Controlled
Substances; Notice of Application; GE
Healthcare
I
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 31, 2012,
GE Healthcare, 3350 North Ridge
Avenue, Arlington Heights, Illinois
60004–1412, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance
listed in schedule II.
The company plans to manufacture a
radioactive product to diagnose
Parkinson’s disease; and to manufacture
a bulk investigational new drug (IND)
for clinical trials.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 229001
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
[FR Doc. 2013–03893 Filed 2–20–13; 8:45 am]
The company plans to manufacture
reference standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
VerDate Mar<15>2010
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03895 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Application;
Alltech Associates, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 19,
2012, Alltech Associates Inc., 2051
Waukegan Road, Deerfield, Illinois
60015, made application to the Drug
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
5-Methoxy-N–Ndimethyltryptamine (7431).
2C–E
(2-(2,5-Dimethoxy-4ethylphenyl)ethanamine) (7509).
2C–H
(2-(2,5Dimethoxyphenyl)ethanamine)
(7517).
2C–T–4 (2-(4-isopropylthio)-2,5dimethoxyphenyl) ethanamine)
(7532).
Schedule
I
I
I
I
The company plans to manufacture
high purity drug standards used for
analytical applications only in clinical,
toxicological, and forensic laboratories.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03919 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cody Laboratories, Inc.
By Notice dated November 1, 2012,
and published in the Federal Register
on November 9, 2012, 77 FR 67398,
Cody Laboratories, Inc., ATTN: Richard
Asherman, 601 Yellowstone Avenue,
Cody, Wyoming 82414, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Dihydromorphine (9145) ................
Amphetamine (1100) ......................
Methamphetamine (1105) ..............
E:\FR\FM\21FEN1.SGM
21FEN1
Schedule
I
II
II
]]>Agencies
[Federal Register Volume 78, Number 35 (Thursday, February 21, 2013)]
[Notices]
[Pages 12102-12103]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-03893]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Sigma Aldrich Research Biochemicals, Inc.
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on November 21, 2012, Sigma
Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick,
Massachusetts 01760-2447, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
[[Page 12103]]
Aminorex (1585)............................ I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
Tetrahydrocannabinols (7370)............... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (MDMA) I
(7405).
Psilocybin (7437).......................... I
5-Methoxy-N,N-diisopropyltryptamine (7439). I
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) I
(7470).
N-Benzylpiperazine (BZP) (7493)............ I
Heroin (9200).............................. I
Normorphine (9313)......................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Nabilone (7379)............................ II
1-Phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Ecgonine (9180)............................ II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Metazocine (9240).......................... II
Methadone (9250)........................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Remifentanil (9739)........................ II
Carfentanil (9743)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture reference standards.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 22, 2013.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-03893 Filed 2-20-13; 8:45 am]
BILLING CODE 4410-09-P
